MDGLMadrigal Pharmaceuticals, Inc.
$471.93+7.3% 1Y
$471.93
$412.3552 weeks$602.83
MDGL in its own filings
MDGL's filing record carries 4 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
352
Events found in the filings · across 1,218 filings · the record starts in 2006
- Hard flags
- 4
Hard flags
- Most recent filing
- Aug 12, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 19, 2006
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Restatement admitted (non-reliance)historical
- 2017-03-31
- Change in certifying accountant3 occurrences
- 2016-09-30
- Late periodic reporthistorical
- 2009-03-17
- Delisting notice / listing-rule failurehistorical
- 2015-12-09
- SEC comment-letter activity17 occurrences
- 2024-01-25
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 12, 2026On August 11, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the …Director or officer change · Form 8-K
- Jul 30, 2026Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates.Earnings release · press release
- Jun 17, 20262026 Stock Plan On June 17, 2026, at the annual meeting of stockholders (the "Annual Meeting") of Madrigal Pharmaceuticals, Inc. (the "Company"), the Company's stockholders approved the Madrigal Pharmaceuticals, Inc. 2026 Stock Plan (the "2026 Stock Plan"), which was previously adopted by the Company's Board of …Director or officer change · Form 8-K
- May 6, 2026Madrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates.Earnings release · press release
- Apr 28, 2026On April 22, 2026, the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) completed a process to reclassify the membership of the Board’s three classes of directors to achieve a more equal apportionment of membership among the three classes following its Annual Meeting of Stockholders …Director or officer change · Form 8-K
- Feb 19, 2026Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results.Earnings release · press release
- Jan 30, 2026On January 29, 2026 (the “Effective Date”), Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment (the “Amendment”) to the Research, Development, and Commercialization Agreement dated as of December 18, 2008 between the …Material agreement entered · Form 8-K
- Dec 11, 2025On December 5, 2025, the Board of Directors of Madrigal Pharmaceuticals, Inc. (the “Company”) appointed Rita Thakkar as Senior Vice President and Chief Accounting Officer of the Company, effective January 12, 2026.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…